FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3188294042> ?p ?o ?g. }

• W3188294042 endingPage "953" @default.
• W3188294042 startingPage "953" @default.
• W3188294042 abstract "Acute myeloid leukemia (AML) carrying inv(16)/t(16;16), resulting in fusion transcript CBFB-MYH11, belongs to the favorable-risk category. However, even if most patients obtain morphological complete remission after induction, approximately 30% of cases eventually relapse. While well-established clinical features and concomitant cytogenetic/molecular lesions have been recognized to be relevant to predict prognosis at disease onset, the independent prognostic impact of measurable residual disease (MRD) monitoring by quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR), mainly in predicting relapse, actually supersedes other prognostic factors. Although the ELN Working Party recently indicated that patients affected with CBFB-MYH11 AML should have MRD assessment at informative clinical timepoints, at least after two cycles of intensive chemotherapy and after the end of treatment, several controversies could be raised, especially on the frequency of subsequent serial monitoring, the most significant MRD thresholds (most commonly 0.1%) and on the best source to be analyzed, namely, bone marrow or peripheral blood samples. Moreover, persisting low-level MRD positivity at the end of treatment is relatively common and not predictive of relapse, provided that transcript levels remain stably below specific thresholds. Rising MRD levels suggestive of molecular relapse/progression should thus be confirmed in subsequent samples. Further prospective studies would be required to optimize post-remission monitoring and to define effective MRD-based therapeutic strategies." @default.
• W3188294042 created "2021-08-16" @default.
• W3188294042 creator A5000486191 @default.
• W3188294042 creator A5003361632 @default.
• W3188294042 creator A5008485103 @default.
• W3188294042 creator A5008526145 @default.
• W3188294042 creator A5014685696 @default.
• W3188294042 creator A5022889391 @default.
• W3188294042 creator A5040398437 @default.
• W3188294042 creator A5040531327 @default.
• W3188294042 creator A5041639951 @default.
• W3188294042 creator A5043263655 @default.
• W3188294042 creator A5050793517 @default.
• W3188294042 creator A5058693120 @default.
• W3188294042 creator A5061319466 @default.
• W3188294042 creator A5061494785 @default.
• W3188294042 creator A5075258869 @default.
• W3188294042 creator A5077942090 @default.
• W3188294042 creator A5077984310 @default.
• W3188294042 creator A5080861890 @default.
• W3188294042 creator A5089889316 @default.
• W3188294042 creator A5089902749 @default.
• W3188294042 date "2021-08-03" @default.
• W3188294042 modified "2023-09-25" @default.
• W3188294042 title "How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring" @default.
• W3188294042 cites W103847125 @default.
• W3188294042 cites W1836196883 @default.
• W3188294042 cites W1836400534 @default.
• W3188294042 cites W1859924037 @default.
• W3188294042 cites W1965922185 @default.
• W3188294042 cites W1966455266 @default.
• W3188294042 cites W1967330415 @default.
• W3188294042 cites W1970740283 @default.
• W3188294042 cites W1971455987 @default.
• W3188294042 cites W1984658294 @default.
• W3188294042 cites W1986025994 @default.
• W3188294042 cites W1988676466 @default.
• W3188294042 cites W1992419693 @default.
• W3188294042 cites W1992826811 @default.
• W3188294042 cites W1995472263 @default.
• W3188294042 cites W1998478685 @default.
• W3188294042 cites W1998812105 @default.
• W3188294042 cites W2001656423 @default.
• W3188294042 cites W2001823585 @default.
• W3188294042 cites W2002766648 @default.
• W3188294042 cites W2004540353 @default.
• W3188294042 cites W2004739140 @default.
• W3188294042 cites W2011654752 @default.
• W3188294042 cites W2013797778 @default.
• W3188294042 cites W2023591716 @default.
• W3188294042 cites W2033109201 @default.
• W3188294042 cites W2034295250 @default.
• W3188294042 cites W2039974386 @default.
• W3188294042 cites W2046202457 @default.
• W3188294042 cites W2046819107 @default.
• W3188294042 cites W2049861380 @default.
• W3188294042 cites W2057968367 @default.
• W3188294042 cites W2059980831 @default.
• W3188294042 cites W2067072111 @default.
• W3188294042 cites W2074192996 @default.
• W3188294042 cites W2074425311 @default.
• W3188294042 cites W2077941080 @default.
• W3188294042 cites W2079933875 @default.
• W3188294042 cites W2082570129 @default.
• W3188294042 cites W2084299345 @default.
• W3188294042 cites W2087049107 @default.
• W3188294042 cites W2093588238 @default.
• W3188294042 cites W2094912768 @default.
• W3188294042 cites W2096756851 @default.
• W3188294042 cites W2098457311 @default.
• W3188294042 cites W2099226078 @default.
• W3188294042 cites W2100663913 @default.
• W3188294042 cites W2103513114 @default.
• W3188294042 cites W2107810465 @default.
• W3188294042 cites W2108379126 @default.
• W3188294042 cites W2109065151 @default.
• W3188294042 cites W2109531585 @default.
• W3188294042 cites W2110828128 @default.
• W3188294042 cites W2114006751 @default.
• W3188294042 cites W2117782490 @default.
• W3188294042 cites W2118574445 @default.
• W3188294042 cites W2123081362 @default.
• W3188294042 cites W2126212760 @default.
• W3188294042 cites W2126283967 @default.
• W3188294042 cites W2138394378 @default.
• W3188294042 cites W2139930402 @default.
• W3188294042 cites W2144395887 @default.
• W3188294042 cites W2146742450 @default.
• W3188294042 cites W2148047805 @default.
• W3188294042 cites W2149858388 @default.
• W3188294042 cites W2151069914 @default.
• W3188294042 cites W2155376978 @default.
• W3188294042 cites W2158862325 @default.
• W3188294042 cites W2158872718 @default.
• W3188294042 cites W2159738043 @default.
• W3188294042 cites W2160746673 @default.
• W3188294042 cites W2162973573 @default.
• W3188294042 cites W2167638087 @default.

• next